TORONTO, Nov. 10, 2011 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) a company focused on non-invasive monitoring of common health risks associated with blood pressure, life style and medication, is pleased to announce they have developed proprietary algorithms that can be utilized on the UFIT generated pulse waveform as a prescreening tool for arrhythmia.
Biosign has published today "UFIT® Detection of Instantaneous Arrhythmic and Amplitude Anomalies" a 916 page report available at www.biosign.com/diaa. This report includes an overview of its current work in this field and in excess of 800 UFIT acquired pulse waveforms that demonstrate UFIT advanced pulse and anomaly detection algorithms for automatic detection of arrhythmic events, followed by classification within a domain.
In current practice, the electrocardiogram (ECG) is utilized for the detection of abnormal electrical activity, which may cause arrhythmic events, i.e., events in which the normal rhythm of the heartbeat is interrupted. The detection of these events is important since they can lead to the deterioration of the mechanical functioning of the heart. While the ECG may be well suited to detect and classify these events, it is not nearly as ubiquitous, nor as simple, a measurement as that of the pulse.
Biosign's UFIT® acquired pulse waveform, or sphygmogram, is a measure of the changes in pulse pressure that occurs within the radial artery at the wrist. Although every electrical contraction of the heart may not result in a pressure wave that travels through the arterial system, every pulse detected by the UFIT® is preceded by a ventricular myocardial contraction. Thus, it follows that irregularities of heartbeats that do not prevent the ejection of blood into the arteries are captured in the sphygmogram. Additionally, evidence suggests that the radial pulse captures arrhythmic events via rate and amplitude changes within the pulse waveform.
"Our company has a long history of focusing on cardiovascular disease and developing new solutions to improve lives around the world" said Dr. Scott Jenkins, Biosign CEO. "With cost effect pre-screening methodology that will find conditions earlier, we can ensure that the correct diagnostic tests are given to the patients who need them".
It is estimated the global cardiovascular disease diagnostics market will reach $12.4 billion by 2015, based on a report by Global Industry Analysts, Inc. Biosign sees these new algorithms imbedded into a standalone application to be utilized as a prescreening test for arrhythmias, as well as a tool for monitoring changes in arrhythmias over time.
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT® medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign, please visit www.biosign.com
This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in, Biosign's filings with Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.